Argos Therapeutics Company Profile (NASDAQ:ARGS)

About Argos Therapeutics

Argos Therapeutics logoArgos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ARGS
  • CUSIP:
Key Metrics:
  • Previous Close: $4.47
  • 50 Day Moving Average: $5.45
  • 200 Day Moving Average: $5.89
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.24
  • P/E Growth: 0.00
  • Market Cap: $184.15M
  • Outstanding Shares: 41,196,000
  • Beta: 1.98
Additional Links:
Companies Related to Argos Therapeutics:

Analyst Ratings

Consensus Ratings for Argos Therapeutics (NASDAQ:ARGS) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.43 (178.04% upside)

Analysts' Ratings History for Argos Therapeutics (NASDAQ:ARGS)
Show:
DateFirmActionRatingPrice TargetDetails
8/11/2016FBR & CoLower Price TargetOutperform$14.00 -> $13.00View Rating Details
6/20/2016Piper Jaffray Cos.Reiterated RatingOverweight$11.00View Rating Details
6/17/2016Needham & Company LLCReiterated RatingBuy$11.00View Rating Details
4/19/2016Roth CapitalBoost Price TargetBuy$11.00 -> $18.00View Rating Details
3/30/2016Stifel NicolausLower Price TargetBuy$16.00 -> $10.00View Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$17.00 -> $12.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$17.00 -> $12.00View Rating Details
6/9/2015MLV & Co.Set Price TargetBuy$13.00View Rating Details
(Data available from 8/24/2014 forward)

Earnings

Earnings History for Argos Therapeutics (NASDAQ:ARGS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2016        
8/10/2016Q2($0.43)($0.48)ViewListenView Earnings Details
5/12/2016Q1($0.56)($0.57)ViewListenView Earnings Details
3/29/2016Q4($0.88)($0.84)ViewListenView Earnings Details
11/16/2015Q315($0.92)($0.97)$158.35 millionViewListenView Earnings Details
8/12/2015Q215($0.80)($0.95)ViewListenView Earnings Details
5/14/2015Q115($0.80)($0.89)ViewListenView Earnings Details
3/30/2015Q314($0.73)($0.83)ViewN/AView Earnings Details
11/13/2014($0.65)($0.77)ViewN/AView Earnings Details
8/13/2014Q214($0.60)($0.61)$1.27 million$1.26 millionViewN/AView Earnings Details
5/13/2014Q114($0.46)($1.05)$1.26 million$0.80 millionViewN/AView Earnings Details
3/27/2014($2.63)($36.19)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Argos Therapeutics (NASDAQ:ARGS)
Current Year EPS Consensus Estimate: $-1.39 EPS
Next Year EPS Consensus Estimate: $-1.38 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.70)($0.54)($0.62)
Q2 20162($0.58)($0.52)($0.55)
Q3 20162($0.33)($0.32)($0.33)
Q4 20162($0.35)($0.30)($0.33)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Argos Therapeutics (NASDAQ:ARGS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Argos Therapeutics (NASDAQ:ARGS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2016International S PharmstandardMajor ShareholderBuy75,474$4.24$320,009.76View SEC Filing  
12/16/2015Andrei Vladimirovich PetrovDirectorBuy5,000$1.80$9,000.00View SEC Filing  
12/16/2015Joan WinterbottomInsiderBuy250$1.83$457.50View SEC Filing  
12/15/2015Alexey Alexandrovic VinogradovDirectorBuy2,000$2.15$4,300.00View SEC Filing  
12/2/2015Jeffrey D AbbeyCEOBuy1,000$3.89$3,890.00View SEC Filing  
11/24/2015Holle Philippe Marie Marce VanDirectorBuy10,000$4.28$42,800.00View SEC Filing  
9/3/2015Holle Philippe Marie Marce VanDirectorBuy12,000$6.27$75,240.00View SEC Filing  
9/1/2015Holle Philippe Marie Marce VanDirectorBuy5,000$6.26$31,300.00View SEC Filing  
8/25/2015Jean LamarreDirectorBuy2,500$6.14$15,350.00View SEC Filing  
8/19/2015Jeffrey D AbbeyCEOBuy5,500$4.75$26,125.00View SEC Filing  
2/12/2014Deventer Sander VanDirectorBuy36,416$8.00$291,328.00View SEC Filing  
2/12/2014International S PharmstandardMajor ShareholderBuy1,275,000$8.00$10,200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Argos Therapeutics (NASDAQ:ARGS)
DateHeadline
finance.yahoo.com logoARGOS THERAPEUTICS INC Financials (NASDAQ:ARGS)
finance.yahoo.com - August 23 at 3:35 PM
News IconStock Tracking Lower for the Quarter: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Post News (NASDAQ:ARGS)
www.kentuckypostnews.com - August 21 at 8:19 AM
finance.yahoo.com logoEdited Transcript of ARGS earnings conference call or presentation 10-Aug-16 8:30pm GMT (NASDAQ:ARGS)
finance.yahoo.com - August 18 at 9:00 PM
News IconCrowd Sentiment & Wall Street Views on Argos Therapeutics, Inc. (NASDAQ:ARGS)? - Post News (NASDAQ:ARGS)
www.kentuckypostnews.com - August 18 at 3:42 PM
News IconArgos Therapeutics, Inc.'s (ARGS): Trending Stock - Hot Stocks Point (NASDAQ:ARGS)
www.hotstockspoint.com - August 18 at 3:42 PM
News IconShares Trading Down in Session: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Post News (NASDAQ:ARGS)
www.kentuckypostnews.com - August 16 at 3:38 PM
capitalcube.com logoETF’s with exposure to Argos Therapeutics, Inc. : August 16, 2016 (NASDAQ:ARGS)
www.capitalcube.com - August 16 at 12:11 PM
biz.yahoo.com logoARGOS THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:ARGS)
biz.yahoo.com - August 15 at 9:06 PM
capitalcube.com logoArgos Therapeutics, Inc. :ARGS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 (NASDAQ:ARGS)
www.capitalcube.com - August 15 at 3:38 PM
globenewswire.com logoArgos Therapeutics Reports Second Quarter 2016 Financial Results and Recent Operational Highlights (NASDAQ:ARGS)
globenewswire.com - August 10 at 10:01 PM
sg.finance.yahoo.com logoArgos Therapeutics reports 2Q loss (NASDAQ:ARGS)
sg.finance.yahoo.com - August 10 at 10:01 PM
biz.yahoo.com logoQ2 2016 Argos Therapeutics Inc Earnings Release - After Market Close (NASDAQ:ARGS)
biz.yahoo.com - August 10 at 9:48 AM
ftsenews.co.uk logoArgos Therapeutics Inc (ARGS) Updated Price Targets - FTSE News (NASDAQ:ARGS)
www.ftsenews.co.uk - August 5 at 11:59 AM
publicnow.com logoArgos Therapeutics to Host Second Quarter 2016 Financial Results Conference Call on Wednesday, August 10, 2016 (NASDAQ:ARGS)
www.publicnow.com - August 4 at 12:04 PM
kcregister.com logoZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) soared 0.83%, Argos Therapeutics, Inc. (NASDAQ:ARGS), Wal-Mart Stores ... - KC Register (NASDAQ:ARGS)
www.kcregister.com - August 1 at 3:32 PM
News IconHot Biotech Stocks Recap: Hemispherx Biopharma, Inc. (NYSEMKT:HEB), Argos Therapeutics, Inc. (NASDAQ:ARGS) - The Voice Registrar (NASDAQ:ARGS)
voiceregistrar.com - July 29 at 3:34 PM
fortune.com logoCurrent Argos Therapeutics, Inc. (NASDAQ:ARGS) PT Means Stock Is Worth Almost $18 - Review Fortune (NASDAQ:ARGS)
reviewfortune.com - July 29 at 3:34 PM
biz.yahoo.com logoARGOS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statem (NASDAQ:ARGS)
biz.yahoo.com - July 29 at 6:12 AM
News IconHot Line At Active Movers- Argos Therapeutics (NASDAQ:ARGS), Noble (NYSE:NE), Exxon Mobil (NYSE:XOM) - Seneca Globe (NASDAQ:ARGS)
www.senecaglobe.com - July 28 at 4:35 PM
fortune.com logoPre-Market Stocks Briefing: Argos Therapeutics Inc(NASDAQ:ARGS), Groupon Inc(NASDAQ:GRPN) - Review Fortune (NASDAQ:ARGS)
reviewfortune.com - July 28 at 4:35 PM
publicnow.com logoArgos Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock and Warrants (NASDAQ:ARGS)
www.publicnow.com - July 28 at 9:48 AM
finance.yahoo.com logoArgos Therapeutics Announces Proposed Public Offering of Common Stock and Warrants - Yahoo Finance (NASDAQ:ARGS)
finance.yahoo.com - July 27 at 9:20 PM
publicnow.com logoArgos Therapeutics Announces Proposed Public Offering of Common Stock and Warrants (NASDAQ:ARGS)
www.publicnow.com - July 27 at 4:28 PM
finance.yahoo.com logo4:08 pm Argos Therapeutics announces proposed public offering of common stock and warrants; details not disclosed (NASDAQ:ARGS)
finance.yahoo.com - July 27 at 4:08 PM
News IconStock Up Nicely This Week: Argos Therapeutics, Inc. (NASDAQ:ARGS) - TGP (NASDAQ:ARGS)
telanaganapress.com - July 23 at 3:33 PM
News IconStock Soars, Rewards Investors Nicely Today: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Engelwood Daily (NASDAQ:ARGS)
www.engelwooddaily.com - July 22 at 8:34 PM
News IconIncreased Volatility Noted on Shares of: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Engelwood Daily (NASDAQ:ARGS)
www.engelwooddaily.com - July 22 at 3:33 PM
News IconIs Argos Therapeutics Inc a Buy? The Stock Rises Again - Press Telegraph (NASDAQ:ARGS)
presstelegraph.com - July 22 at 3:33 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Argos Therapeutics, Inc. (NASDAQ:ARGS) - TGP (NASDAQ:ARGS)
telanaganapress.com - July 21 at 10:43 AM
fiscalstandard.com logoArgos Therapeutics Inc (ARGS) Current Analyst Ratings - Fiscal Standard (NASDAQ:ARGS)
www.fiscalstandard.com - July 21 at 10:43 AM
News IconAfter Today's Huge Increase, Is Argos Therapeutics Inc's Near-Term Analysis Positive? - Press Telegraph (NASDAQ:ARGS)
presstelegraph.com - July 20 at 4:47 PM
news.cmlviz.com logoArgos Therapeutics Inc Stock Technicals Hit Weakness - CML News (NASDAQ:ARGS)
news.cmlviz.com - July 19 at 3:34 PM
News IconArgos Therapeutics, Inc. (NASDAQ:ARGS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:ARGS)
www.engelwooddaily.com - July 19 at 3:34 PM
News IconHow Analysts Feel About Argos Therapeutics Inc (NASDAQ:ARGS)? - Consumer Eagle (NASDAQ:ARGS)
www.consumereagle.com - July 18 at 3:37 PM
News IconTrading Performance and Target Watch for Argos Therapeutics, Inc. (NASDAQ:ARGS) - Press Telegraph (NASDAQ:ARGS)
presstelegraph.com - July 18 at 8:28 AM
News IconShares Moving Down on the Week: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Engelwood Daily (NASDAQ:ARGS)
www.engelwooddaily.com - July 17 at 8:18 AM
News IconArgos Therapeutics Incorporated (NASDAQ:ARGS) Shorts Decreased by 2.74% After Short Covering - Consumer Eagle (NASDAQ:ARGS)
www.consumereagle.com - July 16 at 3:32 PM
News IconEye on Stock Volatility for: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Engelwood Daily (NASDAQ:ARGS)
www.engelwooddaily.com - July 14 at 3:37 PM
streetinsider.com logoArgos Therapeutics (ARGS) Announces Dosing of First Patient in AGS-004 Phase 2 as HIV Treatment - StreetInsider.com (NASDAQ:ARGS)
www.streetinsider.com - July 14 at 3:37 PM
4-traders.com logoArgos Therapeutics : Announces First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in the Treatment of HIV (NASDAQ:ARGS)
www.4-traders.com - July 14 at 12:28 PM
publicnow.com logoArgos Therapeutics Announces First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in the Treatment of HIV (NASDAQ:ARGS)
www.publicnow.com - July 14 at 9:28 AM
News IconArgos Therapeutics Incorporated (NASDAQ:ARGS) Shorts Decreased by 2.74% After Short Covering - Press Telegraph (NASDAQ:ARGS)
presstelegraph.com - July 13 at 3:36 PM
News IconAnalyst Target and Average Rating Watch: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Press Telegraph (NASDAQ:ARGS)
presstelegraph.com - July 13 at 11:40 AM
news.cmlviz.com logoArgos Therapeutics Inc Stock Momentum at Critical Inflection Point - CML News (NASDAQ:ARGS)
news.cmlviz.com - July 12 at 3:38 PM
News IconArgos Therapeutics, Inc. (NASDAQ:ARGS) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:ARGS)
www.engelwooddaily.com - July 12 at 3:38 PM
streetinsider.com logoArgos Therapeutics (ARGS) Names Katz CFO - StreetInsider.com (NASDAQ:ARGS)
www.streetinsider.com - July 11 at 3:34 PM
biz.yahoo.com logoARGOS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Finan (NASDAQ:ARGS)
biz.yahoo.com - July 11 at 8:36 AM
kcregister.com logoWatch List: Argos Therapeutics, Inc. (NASDAQ:ARGS), Veeva Systems Inc. (NYSE:VEEV), KCG Holdings, Inc. (NYSE ... - KC Register (NASDAQ:ARGS)
www.kcregister.com - July 11 at 8:22 AM
finance.yahoo.com logoDr. Richard D. Katz Joins Argos Therapeutics as Chief Financial Officer (NASDAQ:ARGS)
finance.yahoo.com - July 11 at 8:00 AM
News IconArgos Therapeutics Incorporated (NASDAQ:ARGS) Short Interest Decreased By 2.74% - Engelwood Daily (NASDAQ:ARGS)
www.engelwooddaily.com - July 9 at 11:39 AM

Social

Argos Therapeutics (NASDAQ:ARGS) Chart for Wednesday, August, 24, 2016


Last Updated on 8/24/2016 by MarketBeat.com Staff